Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Serina Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 25.40M shares outstanding
USSerina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain.
Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease.
The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Leadership
Balkrishan “Simba” Gill, Ph.D.
Gregory H. Bailey, M.D.
Jay Venkatesan, M.D.
Karen J. Wilson
Employees
12
Country
US
Sector
Healthcare
Website
serinatherapeutics.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Simon Farrell | Director | Grant/Award | 30.5K | -- | Jul 22, 2026 |
 Brannan Stephen K. | Director | Purchase | 1.0K | $2.0K | Jul 7, 2026 |
 Bailey Gregory | Director | Conversion of Derivative | 762.5K | $1.72M | Jun 17, 2026 |
| Bailey Gregory | Director | Conversion of Derivative | 6.67M | $15.00M | Jun 17, 2026 |
| Bailey Gregory | Director | Conversion of Derivative | 1.77M | $3.98M | Jun 17, 2026 |
 Venkatesan Jay | Director | Conversion of Derivative | 96.5K | $217.2K | Jun 17, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
 Bailey Gregory Director | 8.6M | 33.7% | FORM 4 |
Juvenescence Limited · joint filing· filed Jul 2026 | 3.3M+1.1M via warrants | 17.3% | 13D |
Sio Capital Management, LLC | 1.0M | 3.9% | 13F |
Randall Moreadith · may incl. warrants· stale · filed Apr 2024 | 615.0K | 2.4% | 13D |
Broadwood Partners, L.P. · may incl. warrants· filed Nov 2024 | 187.5K | 0.7% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 162.2K | 0.6% | 13F |
Waverly Advisors, LLC | 67.5K | 0.3% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 51.0K | 0.2% | 13F |
Keel Point, LLC | 21.5K | 0.1% | 13F |
NORTHERN TRUST CORP | 20.8K | 0.1% | 13F |
Insiders
- Simon FarrellDirector
- Brannan Stephen K.Director
- Bailey GregoryDirector
- Venkatesan JayDirector
- Marshall Richard PeterDirector
- WILSON KAREN JDirector
- LEDGER STEVEN AChief Executive Officer
- CURHAN GREGORY SChief Financial Officer
- Moreadith RandallChief Scientific Officer
- Tenjarla SriniSVP, CMC & Formulation
based on 25.40M shares outstanding
US30d Avg
82.35K
60d Avg
70.50K
90d Avg
65.61K